A Phase I Study to Evaluate the Safety and Pharmacokinetics of ABBV-399 in Japanese Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2019
Price : $35 *
At a glance
- Drugs Telisotuzumab vedotin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 12 Mar 2019 Status changed from active, no longer recruiting to completed.
- 26 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Mar 2018 Planned End Date changed from 2 Apr 2020 to 19 Jun 2019.